Citeline Podcasts

Norstella
Norstella

Citeline places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge and insight, by providing the perfect combination of news and information together with penetrating insight and analysis. Citeline is a leader in the field of healthcare industry information.

  1. 1d ago

    Rethinking Risk: Why Early Evidence Strategy Matters for Emerging Biotechs

    For emerging biotech companies, development success is often measured by clinical milestones, safety, and efficacy. However, demonstrating an asset’s value extends beyond regulatory approval. Understanding patient needs and treatment experiences, as well as evolving stakeholder expectations, early in development plays an important role in shaping a more informed evidence strategy. In this podcast, Ashwin Rai, Director of Data Science and Advanced Analytics, and Gale Harding, Senior Research Leader, from the PPD clinical research business of Thermo Fisher Scientific, discuss how integrating real-world data and patient-centered insights earlier in development can help developers address evidence gaps, inform critical decisions, and build a stronger foundation for demonstrating treatment value. What the Podcast Explores • Why evidence planning should begin early in asset development, rather than closer to commercialization • How real-world data can help identify unmet needs, understand patient journeys, and inform development decisions, and why more data doesn’t necessarily mean better data • The importance of capturing patient experiences and outcomes beyond traditional clinical endpoints • How patient-centered research can help address evidence gaps and strengthen an asset’s value story • Why evidence strategies must evolve alongside changing stakeholder expectations and development priorities

    Rethinking Risk: Why Early Evidence Strategy Matters for Emerging Biotechs

  2. 4d ago

    Drug Fix: Could Other Products Use Peptide Order For Access, Industry Opposes CRL Release

    Pink Sheet Executive Editor Derrick Gingery, Senior Editor Sue Sutter, Senior Reporter Maaisha Osman and Editor-in-Chief Nielsen Hobbs consider the impact of the Health and Human Services Department’s temporary order allowing compounding of unapproved peptides on the drug industry (1:58), including whether stakeholder could use the precedent to gain access to other products (4:05). They also analyze HHS’ dismissal of US Food and Drug Administration safety concerns (11:28). In addition, the group discusses the Pharmaceutical Research and Manufacturers of America’s opposition to releasing complete response letters and the future of legislative efforts to codify the practice (19:52). More On These Topics From The Pink Sheet HHS Peptide Policy Brushes Off US FDA Safety Concerns As Hypothetical: https://insights.citeline.com/pink-sheet/compliance/manufacturing/hhs-allows-compounding-of-six-unapproved-peptides-UEKWZWETHFG4XJXTVA4VUNE3PU/ Peptides Compounding Would ‘Undermine’ US FDA Drug Approval Process, Ex-Agency Official Argues: https://insights.citeline.com/pink-sheet/pathways-and-standards/approval-standards/peptides-compounding-would-undermine-us-fda-drug-approval-process-ex-agency-official-argues-7RZQLE3HJ5B4FMB3AUREB5LUZU/ US FDA’s Complete Response Letter Postings A Gift To Chinese Competitors, PhRMA Says: https://insights.citeline.com/pink-sheet/product-reviews/complete-response-letters/us-fdas-complete-response-letter-postings-a-gift-to-chinese-competitors-phrma-says-IJ2VETAAGND5NH6CXWADH3R6TU/

    Drug Fix: Could Other Products Use Peptide Order For Access, Industry Opposes CRL Release

  3. Oct 27

    Strategic Intent: Understanding Crossover Strategies in Biotech With Sofinnova Partners’ David Evans

    In this episode of Strategic Intent, Partner at Sofinnova Partners, David Evans discusses his transition from Roche Venture Fund, different investments strategies, general market analysis across Europe and US, as well as growing therapeutics area trends within biotech.

    Strategic Intent: Understanding Crossover Strategies in Biotech With Sofinnova Partners’ David Evans

  4. Oct 22

    Scrip Awards Podcast – Parabilis CEO Mathai Mammen Interview

    Ahead of the awards presentation on Dec 2, the Scrip Awards podcast speaks to Mathai Mammen, CEO of Parabilis, one of the shortlisted companies for Biotech of The Year.

    Scrip Awards Podcast – Parabilis CEO Mathai Mammen Interview

  5. Oct 20

    Strategic Intent: Can Blood Tests Break the Alzheimer’s Diagnosis Bottleneck?

    Disease-modifying Alzheimer’s treatments have arrived, but diagnosing the right patients at scale is still a major bottleneck. In this episode of Strategic Intent, Marion Webb (MedTech Insight) speaks with Dr. Soeren Mattke, research professor of economics at USC, director of the Brain Health Observatory, and member of the scientific advisory board of ALZpath, about how FDA-cleared blood tests are changing the picture. They cover why amyloid PET scans and spinal taps struggle to scale, how p-tau217 blood tests work and who makes them, and how primary care doctors can use them to prioritize patients and better prepare referrals to overstretched neurologists. They also discuss test limitations, including false positives and the potential of misdiagnosis when patients have other diseases like kidney disease and obesity, why screening people without symptoms isn’t recommended yet, and the economics: roughly $5,000 for a PET scan versus about $125 for a Medicare-reimbursed blood test. Follow the In Vivo podcast on Apple Podcasts and Spotify to stay ahead of what’s shaping life sciences next.

  6. Oct 19

    Off-Patent, On Record: Unlocking The Value Of Biosimilars Beyond Savings With IGBA’s Ana Gaunt

    In the latest episode of Off-Patent, On Record, Generics Bulletin’s senior reporter Urtė Fultinavičiūtė talks to the International Generic and Biosimilar medicines Association’s secretary general Ana Gaunt to mark the start of Global Biosimilars Week, a worldwide awareness and education campaign spotlighting the importance of biosimilars.

    Off-Patent, On Record: Unlocking The Value Of Biosimilars Beyond Savings With IGBA’s Ana Gaunt

  7. Oct 16

    Drug Fix: What Drove US FDA Generics Chief To Step Down And New Rare Disease Framework

    Pink Sheet Executive Editor Derrick Gingery, Senior Editor Sue Sutter and Editor-in-Chief Nielsen Hobbs discuss the reasons Iilun Murphy, director of the US Food and Drug Administration’s Office of Generic Drugs, decided to step down (:53) and whether the move should concern senior agency officials (2:51). They also consider the FDA’s plan to create a fit-for-purpose rare disease approval framework (12:19), how it will connect with the agency’s litany of programs for the products (14:52) and the potential difficulties of systematizing regulatory flexibility (18:22).   More On These Topics From The Pink Sheet US FDA Generic Drugs Office Director Steps Down Amid ‘Political Pressure,’ Admin Burden: https://insights.citeline.com/pink-sheet/biosimilars-and-generics/generics/us-fda-generic-drugs-office-director-steps-down-amid-political-pressure-admin-burden-RSIU23LDWZETDO5XYPAAPCIKVM/ US FDA’s Rare Disease Framework Envisions Systematic Regulatory Flexibility: https://insights.citeline.com/pink-sheet/rare-diseases/us-fdas-rare-disease-framework-envisions-systematic-regulatory-flexibility-CKPMVFWBEVF3DNERAJBZZ23EYA/ US FDA Eyes Adaptive Rare Disease Framework To Replace Piecemeal Flexibilities: https://insights.citeline.com/pink-sheet/rare-diseases/us-fda-eyes-adaptive-rare-disease-framework-to-replace-piecemeal-flexibilities-JU2IHKV76ZHYXDZQBW23BE3FRI/

    Drug Fix: What Drove US FDA Generics Chief To Step Down And New Rare Disease Framework

  8. Oct 15

    Scrip Chinese-Language Podcast - Oct. 14, 2026

    本期播客内容来自《Scrip》杂志，精选内容涵盖截至2026年10月9日当周的生物制药行业的商业动态。本期节目采用人工智能文本转语音及语音仿真技术制作。本周内容包括：中国带来的竞争威胁；第三季度并购活动降温；新型肺炎球菌疫苗竞争者；西班牙生物技术公司的战略；以及盐野义制药20亿美元的收购案。Story links: https://insights.citeline.com/scrip/podcasts/scrips-five-must-know-things/quick-listen-scrips-five-must-know-things-ZCXOSRSNEBCARAW4DUWENVCPSQ/ 向听众们简要更新一下：Scrip现在已在Spotify和Apple Podcasts上开设了专属播客频道。Feedback: podcasts@norstella.com

    Scrip Chinese-Language Podcast - Oct. 14, 2026
See All (640)

4.2
out of 5
30 Ratings

About

Citeline places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge and insight, by providing the perfect combination of news and information together with penetrating insight and analysis. Citeline is a leader in the field of healthcare industry information.

Information

  • Channel
    Norstella
  • Creator
    Norstella
  • Years Active
    2014 - 2026
  • Episodes
    666
  • Rating
    Clean
  • Copyright
    © 24c12740-34d6-11f1-9889-f71e988e8a77
  • Show Website
    Citeline Podcasts

More From Norstella

You Might Also Like